Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Mimedx (MDXG) FCF Margin (2016 - 2025)

Historic FCF Margin for Mimedx (MDXG) over the last 16 years, with Q3 2025 value amounting to 25.62%.

  • Mimedx's FCF Margin rose 24800.0% to 25.62% in Q3 2025 from the same period last year, while for Sep 2025 it was 16.98%, marking a year-over-year increase of 7100.0%. This contributed to the annual value of 18.76% for FY2024, which is 85100.0% up from last year.
  • As of Q3 2025, Mimedx's FCF Margin stood at 25.62%, which was up 24800.0% from 14.44% recorded in Q2 2025.
  • Over the past 5 years, Mimedx's FCF Margin peaked at 25.62% during Q3 2025, and registered a low of 22.53% during Q4 2021.
  • Over the past 5 years, Mimedx's median FCF Margin value was 6.66% (recorded in 2024), while the average stood at 5.43%.
  • In the last 5 years, Mimedx's FCF Margin soared by 251400bps in 2023 and then tumbled by -105900bps in 2025.
  • Over the past 5 years, Mimedx's FCF Margin (Quarter) stood at 22.53% in 2021, then soared by 62bps to 8.46% in 2022, then skyrocketed by 220bps to 10.18% in 2023, then skyrocketed by 96bps to 19.93% in 2024, then increased by 29bps to 25.62% in 2025.
  • Its last three reported values are 25.62% in Q3 2025, 14.44% for Q2 2025, and 5.58% during Q1 2025.